The people-first approach transforming eClinical processes
Pharmaceutical Technology
NOVEMBER 7, 2024
With the boom in eClinical solutions showing no signs of slowing, adding a “human at the center” perspective can help optimize data management
Pharmaceutical Technology
NOVEMBER 7, 2024
With the boom in eClinical solutions showing no signs of slowing, adding a “human at the center” perspective can help optimize data management
Bio Pharma Dive
NOVEMBER 7, 2024
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 7, 2024
The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.
Bio Pharma Dive
NOVEMBER 7, 2024
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
NOVEMBER 7, 2024
Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.
Pharma Times
NOVEMBER 7, 2024
Trial to evaluate safety and efficacy of MVA-BN vaccine
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
NOVEMBER 7, 2024
New initiatives to tackle AI-related challenges in life sciences
Pharmaceutical Technology
NOVEMBER 7, 2024
Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic macular oedema.
pharmaphorum
NOVEMBER 7, 2024
Discover the key takeaways from a webinar focused on boosting recruitment and retention through Social Determinants of Health (SDOH) data. Learn how incorporating SDOH data can enhance your recruitment and retention strategies.
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $7.5m, according to GlobalData's Deals Database.
XTalks
NOVEMBER 7, 2024
Journey Medical Corporation, a leading biopharmaceutical company dedicated to the development and commercialization of innovative dermatology treatments, has announced that the US Food and Drug Administration (FDA) has approved Emrosi (minocycline hydrochloride extended release capsules, 40 mg), formerly referred to as DFD-29, for the treatment of rosacea.
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.
pharmaphorum
NOVEMBER 7, 2024
Sarepta has halted development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy therapy Exondys 51.
Pharmaceutical Technology
NOVEMBER 7, 2024
In Canada pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Fierce Pharma
NOVEMBER 7, 2024
After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring. | After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring, cutting the autoimmune disease biotech's workforce for a second time in less than a year.
Pharmaceutical Technology
NOVEMBER 7, 2024
Discover the top sales and marketing intelligence providers for the pharmaceutical industry, offering predictive insights and data enrichment to drive growth.
pharmaphorum
NOVEMBER 7, 2024
Nasdaq-listed CDMO Avid Bioservices has agreed a $1.
Pharmaceutical Technology
NOVEMBER 7, 2024
Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.
pharmaphorum
NOVEMBER 7, 2024
NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis
Pharmaceutical Technology
NOVEMBER 7, 2024
Funds managed by GHO Capital Partners and Ampersand Capital Partners have signed a definitive agreement to acquire Avid Bioservices.
pharmaphorum
NOVEMBER 7, 2024
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.The Danish group bought rights to ocedurenone, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA), from the Singapore biotech in October 2023 as a companion to its GLP-1-based therapies for reducing cardiovascular risk and kidney disease in people with diabetes and obesity.
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Rethinking Clinical Trials
NOVEMBER 7, 2024
Speakers Anitha S. John, MD, PhD Medical Director Washington Adult Congenital Heart Program Professor of Pediatrics Children’s National Hospital George Washington University Thomas W. Carton, PhD, MS Chief Data and Strategy Officer Louisiana Public Health Institute Slides Keywords Adult Congenital Heart Disease; Registry; Patient Engagement Key Points The research team reviewed the current challenges in adult congenital heart disease (ACHD) clinical
Fierce Pharma
NOVEMBER 7, 2024
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its bread-and-butter antirival franchise with an eye on the potential of its long-acting | Gilead's CAR-T therapies Yescarta and Tecartus have stayed relatively flat all year with its Yescarta facing a 1% decline over the third quarter due to competition.
XTalks
NOVEMBER 7, 2024
Intra-Cellular Therapies recently announced that its schizophrenia treatment, lumateperone (brand name Caplyta), has met the primary endpoint in a late-stage clinical trial. Caplyta is currently approved for the treatment of schizophrenia as well as bipolar I and bipolar II depression in adults. The randomized Study 304 clinical trial, a “withdrawal trial,” was conducted across multiple sites with the goal of assessing the efficacy, safety and tolerability of lumateperone 42 mg for the preventio
Fierce Pharma
NOVEMBER 7, 2024
An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the gene therapy. | An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy Elevidys has sparked a new surge in sales. The gene therapy's $181 million sales in the third quarter beat analysts' expectations as it made a 48% sequential leap.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
NOVEMBER 7, 2024
Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.
pharmaphorum
NOVEMBER 7, 2024
Discover the latest metrics and updates on the UK's VPAG (Voluntary scheme for branded medicines Pricing, Access and Growth) from NICE (National Institute for Health and Care Excellence). Stay informed on this work in progress.
Outsourcing Pharma
NOVEMBER 7, 2024
The Taiwanese biotech has launched a phase 1/2 trial to test its small molecule cancer therapy in children and young adults with relapsed or treatment resistant tumors.
Fierce Pharma
NOVEMBER 7, 2024
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. | Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. But the Massachusetts biotech's RSV shot fell way short of expectations.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content